PACB - Pacific Biosciences of California, Inc.
NEXT EARNINGS:
May 6, 2026
EPS Est: $-0.13
|
Rev Est: $39.9M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$2.74
DETAILS
HIGH:
$4.00
LOW:
$1.50
MEDIAN:
$2.50
CONSENSUS:
$2.74
UPSIDE:
65.06%
Market Cap:
501.17M
Volume:
3,829,686
Avg Volume:
7,773,365
52 Week Range:
0.85-2.73
Sector:
Healthcare
Industry:
Medical - Devices
Beta:
2.28
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
575
IPO Date:
2010-10-27
EPS (TTM):
-1.82
P/E Ratio:
-1.03
Revenue (TTM):
160.00M
Total Assets:
784.08M
Total Debt:
759.46M
Cash & Equiv:
279.51M
Rev Growth (5Y):
15.2%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-76.4%
Debt/Equity:
141.98
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-12 | $-0.12 | $-0.19 | +36.8% | $44.6M | $41.9M | +6.6% |
| 2025-11-05 | $-0.12 | $-0.16 | +25.0% | $38.4M | $44.6M | -13.8% |
| 2025-08-07 | $-0.13 | $-0.18 | +27.8% | $39.8M | $39.9M | -0.5% |
| 2025-05-08 | $-0.15 | $-0.19 | +21.1% | $37.2M | $36.9M | +0.7% |
| 2025-02-13 | $-0.20 | $-0.20 | 0.0% | $39.2M | $40.7M | -3.6% |
| 2024-11-07 | $-0.17 | $-0.20 | +15.0% | $40.0M | $42.0M | -4.7% |
| 2024-08-07 | $-0.20 | $-0.24 | +16.7% | $36.0M | $40.9M | -11.9% |
| 2024-05-09 | $-0.26 | $-0.26 | 0.0% | $38.8M | $43.4M | -10.7% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 160.00M | 154.01M | 200.52M | 128.30M | 130.51M | 78.89M | 90.89M | 78.63M | 93.47M | 90.71M | 92.78M | 60.59M |
| Net Income | (546.38M) | (309.85M) | (306.74M) | (314.25M) | (181.22M) | 29.40M | (84.13M) | (102.56M) | (92.19M) | (74.38M) | (31.70M) | (66.16M) |
| EPS | -1.82 | -1.13 | -1.21 | -1.40 | -0.89 | 0.18 | -0.51 | -0.76 | -0.87 | -0.83 | -0.42 | -0.94 |
| Total Assets | 784.08M | 1.26B | 1.75B | 1.77B | 2.01B | 413.98M | 147.99M | 170.28M | 144.08M | 137.88M | 131.11M | 124.52M |
| Total Debt | 759.46M | 672.43M | 933.93M | 948.48M | 955.36M | 42.00M | 61.67M | 14.66M | 13.63M | 16.11M | 14.95M | 14.12M |
| Cash & Equivalents | 279.51M | 55.37M | 179.91M | 325.09M | 460.73M | 81.61M | 29.63M | 18.84M | 62.87M | 16.77M | 82.27M | 36.45M |
| Operating Cash Flow | 0 | (206.06M) | (266.55M) | (263.21M) | (111.18M) | 19.50M | (78.31M) | (66.43M) | (67.52M) | (67.93M) | (47.89M) | (51.47M) |
| Free Cash Flow | 0 | (212.25M) | (275.39M) | (280.14M) | (117.11M) | 18.46M | (81.15M) | (68.28M) | (77.95M) | (76.14M) | (50.90M) | (53.08M) |
| FCF per Share | N/A | -0.77 | -1.09 | -1.25 | -0.58 | 0.11 | -0.53 | -0.51 | -0.74 | -0.85 | -0.67 | -0.75 |
| Book Value | 5.35M | 506.59M | 701.30M | 562.90M | 790.99M | 335.49M | 54.92M | 114.06M | 86.10M | 84.67M | 73.54M | 54.95M |
| Cash & ST Investments | 279.51M | 389.93M | 631.42M | 772.32M | 1.04B | 318.81M | 49.10M | 102.35M | 62.87M | 71.98M | 82.27M | 101.35M |
| ROC Equity | -102.15 | -0.61 | -0.44 | -0.56 | -0.23 | 0.09 | -1.53 | -0.90 | -1.07 | -0.88 | -0.43 | -1.20 |